ALPS O'Shares Global Internet Giants ETF Shares (OGIG)
- Previous Close
36.49 - Open
36.82 - Bid --
- Ask --
- Day's Range
36.82 - 37.64 - 52 Week Range
26.47 - 39.60 - Volume
11,720 - Avg. Volume
14,709 - Net Assets 146.09M
- NAV 36.53
- PE Ratio (TTM) --
- Yield 0.00%
- YTD Daily Total Return -0.05%
- Beta (5Y Monthly) 1.14
- Expense Ratio (net) 0.48%
Under normal market conditions, the fund will invest at least 80% of its total assets in the components of the underlying index. The underlying index is a rules-based index intended to give investors a means of tracking stocks exhibiting quality and growth characteristics in the "internet sector", as defined by the index provider. The fund is non-diversified.
ALPS
Fund Family
Technology
Fund Category
146.09M
Net Assets
2018-06-05
Inception Date
Performance Overview: OGIG
Trailing returns as of 4/22/2024. Category is Technology.
People Also Watch
Holdings: OGIG
Top 10 Holdings (34.78% of Total Assets)
Sector Weightings
Related ETF News
Research Reports: OGIG
Daily – Vickers Top Buyers & Sellers for 04/19/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Analyst Report: CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
RatingPrice TargetAnalyst Report: CRISPR Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR’s most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
RatingPrice TargetAnalyst Report: CRISPR Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR’s most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
RatingPrice Target